article Open AccessTop 1% cited

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Clinical Cancer Research · 2014 · Vol. 21(5) · pp. 1019–1027

Paul F. Robbins✉Sadik H. KassimThai L.N. Tran(University of California, Irvine)Jessica S. CrystalRichard A. MorganSteven A. FeldmanJames Chih‐Hsin YangMark E. DudleyJohn R. WunderlichRichard M. SherryUdai S. KammulaMarybeth S. HughesNicholas P. RestifoMark RaffeldChyi‐Chia Richard LeeYong F. LiMona El‐GamilSteven A. Rosenberg

View via DOI Publisher page

Abstract

The adoptive transfer of autologous T cells transduced with a retrovirus encoding a TCR against an HLA-A*0201 restricted NY-ESO-1 epitope can be an effective therapy for some patients bearing synovial cell sarcomas and melanomas that are refractory to other treatments.

CAR-T cell therapy research Immunotherapy and Immune Responses Virus-based gene therapy researchMedicineSynovial sarcomaAdoptive cell transferPeripheral blood mononuclear cellT-cell receptorMelanomaResponse Evaluation Criteria in Solid TumorsCancer researchT cellImmunotherapy

MeSH terms

AdultAgedAntigens, NeoplasmFemaleFollow-Up StudiesHumansMaleMelanomaMembrane ProteinsMiddle AgedNeoplasm MetastasisPhenotypePilot ProjectsReceptors, Antigen, T-CellSarcoma, Synovial